Reduced CB1R signaling in mice lacking the CB1R gene (CNR1), in fact, results in more severe motor deficits and synaptic pathology linked to neurodegenerative damage after EAE [20, 21], and human subjects carrying a genetic variant of CNR1 associated with reduced CB1R protein expression have higher risk of progressive MS course [22], and more severe relapsing MS disease course [23], and neurodegenerative damage [24]. Here, CNR1 is linked to myeloid sarcoma.